DAEWOONG PHARMA: debt-to-equity, ROE and more
KOSPI, Legal name DAEWOONG PHARMA
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 108.2%
- Equity ratio
- 48.0%
- ROE
- 17.0%
- Op. margin
- 12.5%
- Rev. growth
- 10.4%
- Interest coverage
- n/a
Condition flags
- Operating profit for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
| Fiscal year | Cash dividend per share | Payout ratio |
|---|---|---|
| 2025 | ₩600 | 3.5% |
| 2024 | ₩600 | 27.9% |
| 2023 | ₩600 | 5.7% |
Cash dividends for 3 straight years (only the 3 years OpenDART returns).
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 101.5% | 49.6% | 4.3% | 7.7% | n/a |
| FY2022 consolidated | 110.9% | 47.4% | 5.3% | 7.5% | 11.0% |
| FY2023 consolidated | 94.1% | 51.5% | 13.2% | 8.9% | 7.4% |
| FY2024 consolidated | 113.3% | 46.9% | 2.5% | 10.4% | 3.4% |
| FY2025 consolidated | 108.2% | 48.0% | 17.0% | 12.5% | 10.4% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩1.15T | ₩1.28T | ₩1.38T | ₩1.42T | ₩1.57T |
| Operating profit | ₩88.9B | ₩95.8B | ₩122.6B | ₩147.9B | ₩196.8B |
| Pre-tax income | ₩19.9B | ₩38.3B | ₩122.0B | ₩56.6B | ₩191.8B |
| Net income | ₩30.3B | ₩39.2B | ₩120.0B | ₩23.3B | ₩192.9B |
| Total assets | ₩1.42T | ₩1.56T | ₩1.77T | ₩1.98T | ₩2.36T |
| Total liabilities | ₩712.8B | ₩822.1B | ₩858.0B | ₩1.05T | ₩1.23T |
| Total equity | ₩702.4B | ₩741.2B | ₩912.3B | ₩927.0B | ₩1.13T |
| Paid-in capital | ₩29.0B | ₩29.0B | ₩29.0B | ₩29.0B | ₩29.0B |
| Debt/equity (source value) | 101.5% | 110.9% | 94.1% | 113.3% | 108.2% |
Company outline (FSC)
- Market
- KOSPI
- Fiscal year end
- Dec
- Founded
- 2002-10-01
- Listed
- 02/11/01
- Employees
- 1,794
- Auditor
- 한영회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1348110075342
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 대웅제약Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.